Case History: Talzenna® (Talazoparib)—A Highly Potent, Orally Efficacious PARP Inhibitor for the Treatment of BRCA-Mutated, HER2-Negative Breast Cancer Patients
2019
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI